Your browser doesn't support javascript.
loading
Ultra-Deep Sequencing Reveals the Mutational Landscape of Classical Hodgkin Lymphoma.
Gomez, Felicia; Fisk, Bryan; McMichael, Joshua F; Mosior, Matthew; Foltz, Jennifer A; Skidmore, Zachary L; Duncavage, Eric J; Miller, Christopher A; Abel, Haley; Li, Yi-Shan; Russler-Germain, David A; Krysiak, Kilannin; Watkins, Marcus P; Ramirez, Cody A; Schmidt, Alina; Martins Rodrigues, Fernanda; Trani, Lee; Khanna, Ajay; Wagner, Julia A; Fulton, Robert S; Fronick, Catrina C; O'Laughlin, Michelle D; Schappe, Timothy; Cashen, Amanda F; Mehta-Shah, Neha; Kahl, Brad S; Walker, Jason; Bartlett, Nancy L; Griffith, Malachi; Fehniger, Todd A; Griffith, Obi L.
Afiliación
  • Gomez F; Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri.
  • Fisk B; McDonnell Genome Institute, Department of Medicine, Washington University School of Medicine, St Louis, Missouri.
  • McMichael JF; Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri.
  • Mosior M; Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri.
  • Foltz JA; McDonnell Genome Institute, Department of Medicine, Washington University School of Medicine, St Louis, Missouri.
  • Skidmore ZL; McDonnell Genome Institute, Department of Medicine, Washington University School of Medicine, St Louis, Missouri.
  • Duncavage EJ; Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri.
  • Miller CA; McDonnell Genome Institute, Department of Medicine, Washington University School of Medicine, St Louis, Missouri.
  • Abel H; Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri.
  • Li YS; Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri.
  • Russler-Germain DA; McDonnell Genome Institute, Department of Medicine, Washington University School of Medicine, St Louis, Missouri.
  • Krysiak K; Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri.
  • Watkins MP; Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri.
  • Ramirez CA; McDonnell Genome Institute, Department of Medicine, Washington University School of Medicine, St Louis, Missouri.
  • Schmidt A; Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri.
  • Martins Rodrigues F; McDonnell Genome Institute, Department of Medicine, Washington University School of Medicine, St Louis, Missouri.
  • Trani L; Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri.
  • Khanna A; Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri.
  • Wagner JA; Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri.
  • Fulton RS; McDonnell Genome Institute, Department of Medicine, Washington University School of Medicine, St Louis, Missouri.
  • Fronick CC; Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri.
  • O'Laughlin MD; Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri.
  • Schappe T; Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri.
  • Cashen AF; Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri.
  • Mehta-Shah N; McDonnell Genome Institute, Department of Medicine, Washington University School of Medicine, St Louis, Missouri.
  • Kahl BS; Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri.
  • Walker J; McDonnell Genome Institute, Department of Medicine, Washington University School of Medicine, St Louis, Missouri.
  • Bartlett NL; Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri.
  • Griffith M; McDonnell Genome Institute, Department of Medicine, Washington University School of Medicine, St Louis, Missouri.
  • Fehniger TA; McDonnell Genome Institute, Department of Medicine, Washington University School of Medicine, St Louis, Missouri.
  • Griffith OL; Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri.
Cancer Res Commun ; 3(11): 2312-2330, 2023 11 15.
Article en En | MEDLINE | ID: mdl-37910143
ABSTRACT
The malignant Hodgkin and Reed Sternberg (HRS) cells of classical Hodgkin lymphoma (cHL) are scarce in affected lymph nodes, creating a challenge to detect driver somatic mutations. As an alternative to cell purification techniques, we hypothesized that ultra-deep exome sequencing would allow genomic study of HRS cells, thereby streamlining analysis and avoiding technical pitfalls. To test this, 31 cHL tumor/normal pairs were exome sequenced to approximately 1,000× median depth of coverage. An orthogonal error-corrected sequencing approach verified >95% of the discovered mutations. We identified mutations in genes novel to cHL including CDH5 and PCDH7, novel stop gain mutations in IL4R, and a novel pattern of recurrent mutations in pathways regulating Hippo signaling. As a further application of our exome sequencing, we attempted to identify expressed somatic single-nucleotide variants (SNV) in single-nuclei RNA sequencing (snRNA-seq) data generated from a patient in our cohort. Our snRNA analysis identified a clear cluster of cells containing a somatic SNV identified in our deep exome data. This cluster has differentially expressed genes that are consistent with genes known to be dysregulated in HRS cells (e.g., PIM1 and PIM3). The cluster also contains cells with an expanded B-cell clonotype further supporting a malignant phenotype. This study provides proof-of-principle that ultra-deep exome sequencing can be utilized to identify recurrent mutations in HRS cells and demonstrates the feasibility of snRNA-seq in the context of cHL. These studies provide the foundation for the further analysis of genomic variants in large cohorts of patients with cHL.

SIGNIFICANCE:

Our data demonstrate the utility of ultra-deep exome sequencing in uncovering somatic variants in Hodgkin lymphoma, creating new opportunities to define the genes that are recurrently mutated in this disease. We also show for the first time the successful application of snRNA-seq in Hodgkin lymphoma and describe the expression profile of a putative cluster of HRS cells in a single patient.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Enfermedad de Hodgkin Límite: Humans Idioma: En Revista: Cancer Res Commun Año: 2023 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Enfermedad de Hodgkin Límite: Humans Idioma: En Revista: Cancer Res Commun Año: 2023 Tipo del documento: Article